Blog

The EY Pulse of the MedTech Industry Report 2025 indicates that the global medical technology (MedTech) sector is robust, with strong financial fundamentals and a heightened focus on high-growth, differentiated innovation despite geopolitical uncertainty and trade headwinds. &nbsp; Key Financial Insights and Market Trends 📈Resilient Revenue Growth: The industry recorded its seventh consecutive year of top-line growth, reaching approximately US$584 Billion. Commercial leaders are projected to achieve 6% to 7% revenue growth again."Safe Harbour" Status: MedTech is proving to be a relative "safe harbour" compared to the broader healthcare industry, with strong performance in areas like orthopaedics (16% revenue growth) and ophthalmics (28% surge). Concentrated Funding: Investment activity is characterized by fewer, larger deals: Venture Capital (VC): Total VC investment climbed 20% to US$8.7 Billion, but the number of rounds dropped 47%. The average round swelled significantly to US$37 Million. M&amp;A Focus: Total M&amp;A spending was below historical norms, but the average deal size increased substantially (up 72% over the decade average), with a focus on acquiring later-stage, high-growth assets closer to profitability. High-Growth Segments: Investor confidence is concentrated in technologies driving differentiated innovation in key therapeutic areas: Robotics Pulse Field Ablation (PFA) Structural Heart Diabetes &nbsp; Strategic Imperatives for MedTech Leaders 💡 The report highlights that sustained success will depend on companies proactively addressing several strategic challenges: Proving the "Right to Grow": Companies must demonstrate not just growth, but the ability to earn that growth through healthy margins and effective capital allocation.Advanced Operating Models: Organizing around autonomous business units (rather than a strictly regional model) is proving to outperform competitors. Adapting to Trade Friction: Companies are compelled to build tariff task forces and reconfigure supply chains, often shifting towards "local-for-local" manufacturing to mitigate risk from trade uncertainty. Harnessing AI: Integrating advanced data and Artificial Intelligence (AI) tools is critical for transforming operations, enhancing diagnostics, and improving supply chain resilience. Source: <a data-mce-href="https://www.ey.com/en_us/life-sciences/pulse-of-medtech-industry-outlook" href="https://www.ey.com/en_us/life-sciences/pulse-of-medtech-industry-outlook" title="https://www.ey.com/en_us/life-sciences/pulse-of-medtech-industry-outlook" target="_blank" rel="noopener">https://www.ey.com/en_us/life-sciences/pulse-of-medtech-industry-outlook</a>

EY 'Pulse of the MedTech Industry Report 2025'

The UCLPartners report, "State of the Nation: Insights from UK Health Innovators," reveals significant systemic barriers that are slowing the adoption and scaling of new technologies and innovations within the NHS.The report, which is based on in-depth interviews with over 50 digital health innovators in England, highlights obstacles that prevent the NHS from fully leveraging health innovation to improve patient care, ease workforce pressure, and stimulate economic growth.Key Findings and Barriers The central finding is that while the UK has a vibrant health innovation sector, the process of adoption by the NHS is often stalled.Low Success Rate in Scaling: Only 28% of the interviewed innovators had been successfully procured and scaled across the NHS.'Pilotitis': Many innovators reported being stuck in 'pilotitis,' where initial trials do not transition into long-term, routine use, as NHS Trusts often "not know which horse to back." Fragmented Systems: Innovators struggle to navigate the complex, often fragmented regulatory and procurement pathways across different NHS organisations (Trusts and Integrated Care Boards). NHS Staff Capacity: NHS staff often reported having "no time, no support, and no incentives" to engage with and implement new innovations. Calls to Action and Recommendations UCLPartners urges policymakers, regulators, NHS leaders, and industry to collaborate to implement practical reforms to speed up progress. Key recommendations include:National Innovation Strategy: Developing a cohesive national strategy with clearer demand signalling from the NHS. Standardised Processes: Implementing standardised procurement and funding routes across NHS Trusts and Integrated Care Boards (ICBs) to reduce fragmentation. Clinician-Innovator Collaboration: Creating the right conditions for clinicians and innovators to work together effectively, ensuring innovation is rooted in real-world problems rather than abstract solutions. The report's purpose is to tackle these systemic barriers, unlocking the potential for faster adoption of proven technologies, which would ultimately improve patient outcomes, create efficiencies within the health service, and support the growth of the UK's life sciences sector.Source: <a data-mce-href="https://s42140.pcdn.co/wp-content/uploads/State-of-the-Nation_Report_-1.pdf" href="https://s42140.pcdn.co/wp-content/uploads/State-of-the-Nation_Report_-1.pdf" title="https://s42140.pcdn.co/wp-content/uploads/State-of-the-Nation_Report_-1.pdf" target="_blank" rel="noopener" data-mce-selected="inline-boundary">https://s42140.pcdn.co/wp-content/uploads/State-of-the-Nation_Report_-1.pdf</a>

State of the Nation: Insights from UK Health Innovators report from UCL Partners

The leading Medtech advisors in Europe include specialized boutique firms dedicated to healthcare technology as well as global consulting and investment banks with extensive medical technology expertise. Nelson Advisors is widely recognised as a prominent boutique M&amp;A and advisory firm in the sector, offering deep market knowledge and a “founders for founders” approach. Other major advisors include global firms like Deloitte, Rothschild &amp; Co, and Houlihan Lokey, all delivering comprehensive support for M&amp;A, investment, and strategy in Medtech and HealthTech.Top Boutique MedTech AdvisorsNelson Advisors: Specialised in European healthcare tech, digital health, Health IT, and AI-driven health solutions. Known for personalized M&amp;A and investment guidance. Entourage: Noted for regulatory, clinical, and quality management consulting. Based in Munich, Basel, and Milan, with expertise in strategic and operational regulatory challenges. ConAlliance: Premier firm focused on M&amp;A advisory services within healthcare, emphasizing tailored solutions for global clients. Major Global &amp; European Firms Deloitte: Consistently among the top mid-market M&amp;A and strategy advisors for life sciences and Medtech in Europe. Rothschild &amp; Co: Leading by deal volume and value, especially for large and complex healthcare tech transactions. Houlihan Lokey: Known for dedicated healthcare teams and expertise in capital-raising and M&amp;A for European medical technology clients. KPMG, PwC, Morgan Stanley, Goldman Sachs, and Moelis &amp; Company: All are active in healthtech and Medtech transactions at various scales, especially in broader healthcare advisory. Highly Regarded Medtech Consulting Specialists RQM+: Regulatory, quality, and clinical consulting services for the medical device and diagnostics industries, serving clients across Europe. MTRC: Specialist in market access, reimbursement, and HTA consulting, supporting Medtech companies operate efficiently in over 20 European countries. Effectum Medical: Swiss-based, offers compliance, quality, and regulatory support for market access in the EU and UK. UK and Northern Europe SpecialistsTHAY Medical, Sensus Group, Haughton Design, Advena Medical, Meddev Solutions, and Flintloque: All provide targeted advisory and regulatory consulting for UK and Northern Europe-based Medtech clients. These advisors offer a full range of services, including buy- and sell-side M&amp;A, fundraising, regulatory consulting, due diligence, portfolio optimization, strategic partnerships, and reimbursement strategy. Nelson Advisors and Entourage are particularly notable for their deep sector specialization and involvement in high-growth subsegments such as digital health and AI-driven healthcare innovation.Source: <a data-mce-href="https://www.perplexity.ai/search/c4a65955-5aea-4614-813b-e9b51b858a2c" href="https://www.perplexity.ai/search/c4a65955-5aea-4614-813b-e9b51b858a2c" title="https://www.perplexity.ai/search/c4a65955-5aea-4614-813b-e9b51b858a2c" target="_blank" rel="noopener">https://www.perplexity.ai/search/c4a65955-5aea-4614-813b-e9b51b858a2c﻿</a>

Who are the leading MedTech advisors in Europe?

The MedTech M&amp;A landscape in the second half of 2025 (H2 2025) is characterised by strategic acquirers with significant cash reserves pursuing high-growth, innovative assets. Valuation multiples are driven by a blend of macro-economic conditions, financial performance, and technological differentiation.Here are 10 Key Variables driving MedTech M&amp;A valuation multiples in H2 2025:1. AI Integration and Proprietary Algorithms Companies with proven, proprietary Artificial Intelligence (AI) or Machine Learning (ML) algorithms for diagnostics, predictive analytics, or imaging analysis are commanding the highest multiples. This is a premium driver, as buyers pay for the competitive edge and efficiency gains that AI delivers in a value-based care world.2. Strength and Defensibility of Intellectual Property (IP) A robust and well-defended IP portfolio, particularly a strong patent moat around core technology (e.g., in robotics, advanced materials, or specialized procedures), significantly increases multiples by reducing the risk of competition and ensuring long-term revenue streams.3. Recurring Revenue Model (SaaS-ification) The shift to Software-as-a-Service (SaaS) models, where revenue is generated from subscriptions, consumables, or long-term service contracts (rather than just the initial device sale), is rewarded with high multiples due to greater revenue predictability and stability.4. Alignment with Value-Based Care (VBC) Companies whose technology provides measurable cost savings or improved patient outcomes (e.g., remote patient monitoring, chronic disease management platforms, or devices that reduce hospital readmissions) are fetching higher valuations. They offer a strategic fit with the payer/provider shift to VBC.5. Revenue Growth Trajectory and Quality of Margins Valuations are heavily influenced by the sustainability of revenue growth and high gross margins. Buyers are scrutinizing the quality of the revenue—is it concentrated in one customer, or is it diversified, scalable, and high-margin? Proven gross margins above the sector average drive premium multiples.6. Regulatory Status and Clarity (De-risking) A target company that has already secured FDA approval (PMA or 510(k) clearance) or the necessary international regulatory approvals (e.g., CE Mark) is seen as significantly de-risked. This clarity accelerates the time-to-market for the acquirer and warrants a higher multiple.7. Strategic Niche and Dominance in High-Growth Sub-Sectors Multiples are higher for companies with dominance in fast-growing, highly specialized niches, such as:Minimally Invasive Surgery (e.g., robotics, advanced visualization) Cardiovascular/Structural Heart Orthopedics/Spine (e.g., advanced fixation or implant technologies) Advanced Diagnostics (e.g., multi-omic testing). 8. Interoperability and Data Access The ability of the device/platform to seamlessly integrate and exchange data with existing Electronic Health Records (EHRs) and hospital IT systems is crucial. High multiples go to solutions that enable efficient data flow and support clinical decision-making.9. Management Team and Cultural Fit An experienced, proven management team with a strong track record of commercial execution and regulatory navigation commands a premium. Furthermore, a perceived cultural fit that simplifies post-merger integration (and reduces key employee flight risk) is directly factored into the valuation.10. Financial Environment (Cost of Capital) Macro factors, particularly the cost of capital (interest rates), play a key role. As interest rates potentially stabilize or decline in H2 2025, the cost of financing M&amp;A deals decreases, increasing the strategic buyers' capacity and willingness to pay higher multiples for attractive assets.To discuss how Nelson Advisors can help your MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

10 Key Variables driving MedTech M&A valuation multiples in H2 2025

Abstract View of Blue Translucent Acrylic Sheets in Dynamic Arrangement

Alignment is critically important in HealthTech Mergers and Acquisitions (M&amp;A) because the consequences of misalignment, in a sector dealing with highly sensitive patient data, complex regulatory hurdles, and life-critical operations, are severe.Failure to align can lead to deal collapse, loss of key talent, significant regulatory fines (e.g., for HIPAA violations), disruption of patient care, and a failure to realize the intended strategic value (synergies) of the merger.Key Areas of Alignment in HealthTech M&amp;A Alignment must be achieved across several interconnected dimensions to ensure a successful integration:1. Strategic and Mission Alignment The core goal of the transaction must be shared and understood by both organizations.Unified Vision: Both parties must agree on the future direction of the combined entity. For a HealthTech acquisition, this could be whether the focus is on scaling a new technology (e.g., AI diagnostics) or expanding a service line (e.g., telehealth). Value Realisation: The intended financial and operational synergies must be clearly defined. If the buyer is acquiring a technology company to save costs, but the seller is focused on rapid market expansion, their strategies and resource allocation plans will immediately clash. 2. Regulatory and Compliance Alignment This is a distinctive and high-stakes area in HealthTech due to strict data privacy and security laws.Data Security and Privacy: Companies must align on policies and infrastructure compliance with regulations like HIPAA (US) or GDPR (EU). Mismanagement of a patient data breach post-merger can lead to massive fines and reputational damage, immediately destroying deal value. Clinical and Quality Standards: Alignment on clinical protocols and quality management systems (QMS) is necessary. Merging two different standards of care or quality control can disrupt service delivery and compromise patient safety. 3. Technology and Data Alignment The seamless integration of complex and often proprietary systems is essential for HealthTech.Interoperability: The acquired technology must be able to talk to the buyer's existing Electronic Health Records (EHRs), billing, and operational systems. Lack of interoperability creates expensive, manual data-transfer headaches that undermine the technology's value. System Roadmaps: An aligned plan for which systems will be integrated, decommissioned, or scaled is crucial. Technical debt or incompatible platforms can slow down innovation and delay synergy realization for years. 4. Cultural and People Alignment Often cited as the primary reason M&amp;A fails, cultural alignment is magnified in the clinical and tech environment.Patient-Centricity vs. Tech-First: A classic clash occurs when a provider organization (focused on patient care, safety, and established workflows) acquires a startup (focused on rapid innovation, disruption, and speed). Their beliefs, behaviors, and decision-making processes must be harmonized. Talent Retention: Misalignment in compensation, benefits, leadership style, or work environment leads to the departure of key engineers, developers, and clinical leaders—the very talent the buyer sought to acquire. Losing these essential employees (often with deep institutional or technical knowledge) can cripple the acquired product or service.critical importance of alignment in healthtech M&amp;A.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Critical importance of alignment in HealthTech M&A

Nelson Advisors have accepted an invitation to present to the Healthcare Club at the IESE Business School, Barcelona in December 2025. The Founding Partners of Nelson Advisors believe strongly in sharing their experiences and knowledge of the HealthTech and MedTech markets with students across a wide range of UK and European Universities ranging from Oxford University and University of Cambridge to London Business School and University College London Global Business Schood for Health to IESE Business School. &nbsp;&nbsp; IESE Business School &nbsp;&nbsp; IESE Business School is the graduate business school of the University of Navarra, with its main campus located in Barcelona, Spain. It is consistently ranked among the top business schools globally, particularly for its MBA and Executive Education programs. &nbsp;&nbsp; Key Characteristics &nbsp;&nbsp; Global Mindset: IESE has a strong international focus with a highly diverse student body and campuses in Barcelona, Madrid, New York, Munich, and São Paulo. Case Method: The school is well-known for its extensive use of the case method, a teaching approach that uses real-world business problems to develop students' critical thinking, problem-solving, and decision-making skills. Values-Based Leadership: IESE emphasises a people centred vision and a commitment to ethics and social responsibility, aiming to educate leaders who can have a positive impact on business and society. &nbsp;&nbsp; Programmes &nbsp;&nbsp; IESE offers a variety of programs, including: &nbsp;&nbsp; Full-time MBA: A 15- or 19-month program known for its global approach. The curriculum includes core courses in the first year and a wide selection of electives in the second.&nbsp; Executive MBA (EMBA): A part-time program designed for experienced professionals. Global Executive MBA (GEMBA): A blended program with on-campus and online components. Executive Education Programs: These are consistently ranked among the best in the world and are aimed at functional managers, senior executives, and C-suite leaders. &nbsp;&nbsp; Rankings and Reputation &nbsp;&nbsp; IESE's programs are highly regarded in international rankings. Recent rankings include: &nbsp;&nbsp; Financial Times Global MBA Ranking: Consistently ranked in the top 10, with a #3 ranking in 2025. The Economist Full-time MBA Ranking: Ranked #1 in the world in 2021. Financial Times Executive Education: Ranked #1 for six consecutive years (2015-2020) and continues to be highly ranked.The school holds triple accreditation from AACSB, AMBA, and EQUIS. &nbsp;&nbsp; IESE Business School &gt; Healthcare Club &nbsp;&nbsp; The IESE Business School Healthcare Club is a professional student club at IESE that focuses on the healthcare industry. Its mission is to support IESE students who are interested in pursuing a career in healthcare by providing them with the resources, knowledge, and networking opportunities they need. &nbsp;&nbsp; The club's activities are designed to help students: &nbsp;&nbsp; Learn about the healthcare sector: They organize seminars, workshops, and panels with industry experts, IESE professors, and alumni. These events cover various aspects of the healthcare industry, from pharmaceuticals and medical devices to digital health and healthcare consulting.Network with industry professionals: The club facilitates connections with leading healthcare companies, startups, and alumni. They host networking events, company visits, and an annual "Healthcare Day" conference, which brings together top professionals to discuss current trends and challenges in the industry.Find a job in the healthcare sector: The club offers career support through CV/cover letter workshops, interview preparation, and a mentorship program that connects students with experienced professionals. They also organize career treks to major healthcare hubs like Basel, Switzerland, and Madrid, Spain, where students can visit companies and network with potential employers.The IESE Healthcare Club plays a key role in positioning the IESE MBA as a source of top talent for healthcare companies and is a valuable resource for students aiming to transition into or advance their careers in this dynamic and impactful industry.

Nelson Advisors

Blog

EY 'Pulse of the MedTech Industry Report 2025'

State of the Nation: Insights from UK Health Innovators r...

Who are the leading MedTech advisors in Europe?

10 Key Variables driving MedTech M&A valuation multiples ...

Critical importance of alignment in HealthTech M&A

Nelson Advisors invited to present to the Healthcare Club...